Drug Trial Radar · NCT05708677
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
22
Planned (sponsor's estimate)
Start
Feb 9, 2021
Primary completion
Feb 2036
Study completion Aug 2036
Sponsor
- Lead sponsor
- Abeona Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Long-Term Extension Study for Participants Previously Treated with EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Conditions
- RDEB
Interventions
EB-101Biological
This is non-interventional and follows patients treated with EB-101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Wound ClosureTime frame: 5 years
- Pain Severity Scale (Wong-Baker FACES)Time frame: 5 years
- Itch Severity ScaleTime frame: 5 years
- Zarit Burden Interview ScaleTime frame: 5 years
- Quality of Life in Epidermolysis BullosaTime frame: 5 years
- Caregiver Global Impression of Change for Pain ScaleTime frame: 5 years
- Wound Infection and Adverse EventsTime frame: 5 years
- The number of treatment-emergent adverse events.Time frame: 5 years
- Serious Adverse EventsTime frame: 5 years
- Incidence of squamous cell carcinoma.Time frame: 5 years
- Replication-competent retrovirus (RCR) statusTime frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Redwood City, California
University of Massachusetts Medical School
Worcester, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.